Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 3, 2006, Pages 123-141

  Ziemniak, Witold ^a,b  

^a Center of Gastrology   (Poland)

^b Centrum Gastrologiczne   (Poland)

Author keywords

Antibiotics; Helicobacter pylori; Resistance to antibiotics

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; CLARITHROMYCIN; LACIDOFIL; METRONIDAZOLE; PANTOPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG; VENTRISOL;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MALE; METRONIDAZOLE; MIDDLE AGED; PROBIOTICS; PROTON PUMP INHIBITORS; STOMACH ULCER; TINIDAZOLE; TREATMENT OUTCOME;

EID: 33750402825     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. The Eurogast Study group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993; 341: 1359-1362.
2. Huang J.Q., Zheng GF, Sumanac K., Irvine EJ, Hunt RH. Meta-analysis of relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 2003; 125(6) 1636-1644.
3. Bielański W. Epidemiological study on Helicobacter pylori infection and extragastroduodenal disorders in Polish population. J Physiol Pharmacol.1999; 50, 5: 723-733.
4. Sipponen P, Varis K, Fraki O, Korri UM, Seppala K, Siurala M. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol 1990; 25: 966-973.
5. Sipponen PK, Seppala M, Kettunen U. Chronic gastritis and gastroduodenal ulcer: a case-control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut 1989; 30: 922-929.
6. 13C-urea in the diagnosis of Helicobacter pylori infection. J Physiol Pharmacol 1996; 47, 3: 545-553.
7. Infection with Helicobacter pylori. In: IARC Working Group on the ewaluation of Carcinogenic Risks to humans, schistosomes, liver flukes and Helicobacter pylori: IARC Monographs on the Ewaluation of Carcinogenic Riscs to Humans.61, Lyon, France: International Agency for Research on Cancer 1994; 177-240.
8. Malfertheiner P, Megraud F, Morain C, et al. The European Helicobacter pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16(2): 167-180.
9. Kim TS, Hur JW, Yu MA, Cheigh CI, Kim KN, Pyun YR. Antagonism of Helicobacter pylori by bacteriocins of acid bacteria. J Food Prot 2003; 66, 1: 3-12.
10. Canducci F, Cremonini F, Armuzzi A, et al. Probiotics and Helicobacter pylori eradication. Dig Liver Dis 2002; 34, 2: 81-83.
11. Cremoni F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effect: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97, 11: 2744-2749.
12. Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. App Environ Microbiol 1998; 64, 11: 4573-4580.
13. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14: 1625-1629.
14. Sheu BS, Wu J, Lo CY, et al. Impact of supplement with Lactobacillus and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669-1675.
15. Bazzoli F, Zagari RM, Fossi S, et al. Short term low dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-777.
16. Gisbert JP, Boixeda D, Aller R, De la Serna C, Sanz E, De Argilla M. Helicobacter pylori and bleeding duodenal ulcer; prevalence of the infection, efficacy of three triple therapies and role of eradication in the prevention of recurrent hemorrhage. Med Clin 1999; 112: 161-165.
17. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadriple therapy for treating Helicobacter pylori infection: meta-analysis. Aliment Pharmacol Ther 2003; 17, 9: 1137-1143.
18. Gerassimos JM, Petraki K, Archavlis E, Pericles A, Christoforidis P, Kourtessas D. Omeprazole triple therapy versus omeprazole quadriple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002; 14, 11: 1237-1243.
19. Magraud F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicrob Agents 2000; 16, 4: 507-509.
20. Megraud F, Lamouliatte H. Review article; the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17,11: 1333.
21. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 15;21(10):1263-1272.
22. Zwet AA, Vandenbrouke-Graulis CMJE, Thijs JC, Wouden EJ, Kusters JG. Stable amoxicillin resistance in Helicobacter pylori. Lancet 1998; 352: 1595.
23. Głupczyński Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Springer-Verlag 2001.
24. Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41: 443-449.
25. Goodwin CS. Antimicrobial treatment of Helicobacter pylori infection. Clin Infect Dis1997; 25: 1023-1026.
26. Glupczynski Y, Burette A. Eradicating Helicobacter pylori. Lancet 1992; 339: 54-55 (Letter).
27. Noach LA, Langerberg WL, Bertola MA, Dankert J, Tytgat JN. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26: 321-327.
28. Malekzadech R, Ansari R, Vahedi H, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303.
29. Lehmann FS, Drewe J, Terraciano L, Beglinger C. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 2000; 14: 305-309.
30. Glupczyński Y.Antimicrobial resistance in Helicobacter pylori: a global overviev. Acta Gastroenterol Belg 1998; 61: 357-366.
31. Culture of Helicobacter pylori from gastric biopsies and antimicrobial susceptibility testing. In Lee A., Megraud F. (ed): Helicobacter pylori: techniques for clinical diagnosis and basic research. W.B. Saunders Company, London, 1996; 17-28.
32. Alarcon T, Vega AE, Domingo D, Martinez MJ, Lopez-Brea M. Clarithromycin resistance among Helicobacter pylori strains isolated from children: Prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 2003; 41(1): 486-489.
33. Rożynek E, Dzierżanowska -Fangrat K, Józwiak P, Madaliński K, Dzierżanowska D. Primary resistance of Helicobacter pylori to antimicrobial agents in Polish children. Acta Microbiol Pol 2002; 51 (3): 255-263.
34. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432-1435.
35. Kalach N, Bergeret M, Benhamou PH, Dupont Ch, Raymond J. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001; 39(1): 394-397.
36. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based "rescue therapy" for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-316.
37. Malekzadech R, Ansari R, Vahedi H, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303.
38. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001; 15: 1543-1547.
39. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 527-532.